Advertisement

Virchows Archiv

, Volume 453, Issue 6, pp 599–609 | Cite as

Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20

  • Gianluca Marucci
  • Luca Morandi
  • Elisabetta Magrini
  • Anna Farnedi
  • Enrico Franceschi
  • Rossella Miglio
  • Daniela Calò
  • Annalisa Pession
  • Maria P. Foschini
  • Vincenzo EusebiEmail author
Original Article

Abstract

Thirty-nine glial tumours (28 glioblastomas (GB) and 11 low-grade gliomas) were investigated with DNA microarrays to reveal a possible specific gene expression profile. Unsupervised classification through hierarchical cluster analysis identified two groups of tumours, the first composed of low-grade gliomas and the second mainly composed of GB. Nine genes were identified as most informative: seven were over-expressed in low-grade gliomas and under-expressed in GB; on the contrary, two genes, insulin-like growth factor binding protein 2 (IGFBP-2) and cell division cycle 20 homologue (CDC20), were over-expressed in GB and under-expressed in low-grade tumours. This same genetic profile was confirmed by reverse transcriptase polymerase chain reaction. Immunohistochemistry for IGFBP-2 was positive in 88.8% of the cases of GB and in only one low-grade glioma, whilst CDC20 immunostained 74.1% of the cases of GB and none low-grade glioma. This was confirmed in an additional series of cases studied with immunohistochemistry only. In conclusion, over-expression of mRNA levels of IGFBP-2 and CDC20 is highly related to GB, IGFBP-2 and CDC-20 gene and protein expressions are strongly correlated, and IGFBP-2 and CDC20 immunopositivity can be useful for the identification of GB in small biopsies.

Keywords

Glioblastoma High-grade glioma Gene expression IGFBP-2 CDC20 

Notes

Acknowledgment

We wish to thank Dr. M. Guizzardi for the encouragement to enter into the world of gene array. This work was presented as Presidential free paper at the 3rd Intercontinental Congress of Pathology, May 2008, Barcelona

Conflict of interest statement

We declare that we have no conflict of interest.

References

  1. 1.
    Louis DN, Ohgaki H, Wiestler OD et al (2007) World Health Organization classification of tumours of the central nervous system. IARC, LyonGoogle Scholar
  2. 2.
    Coons SW, Johnson PC, Scheithauer BW et al (1997) Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79:1381–1393PubMedCrossRefGoogle Scholar
  3. 3.
    Nutt CL, Mani DR, Betensky RA et al (2003) Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63:1602–1607PubMedGoogle Scholar
  4. 4.
    Reifenberger G, Louis DN (2003) Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 62:111–126PubMedGoogle Scholar
  5. 5.
    Gajjar A, Hernan R, Kocak M et al (2004) Clinical, histopathologic and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 22:984–993PubMedCrossRefGoogle Scholar
  6. 6.
    Pomeroy SL, Tamayo P, Gaasenbeek M et al (2002) Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415:436–442PubMedCrossRefGoogle Scholar
  7. 7.
    Lossos IS, Czerwinski DK, Alizadeh AA et al (2004) Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350:1828–1837PubMedCrossRefGoogle Scholar
  8. 8.
    van ‘t Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536PubMedCrossRefGoogle Scholar
  9. 9.
    Zahrak M, Parmigiani G, Wayne Y (2007) Pre-processing Agilent microarray data. BMC Bioinformatics 8:142CrossRefGoogle Scholar
  10. 10.
    Smyth GK, Speed TP (2003) Normalization of cDNA microarry data. Methods 31:265–273PubMedCrossRefGoogle Scholar
  11. 11.
    Tibshirani R, Hastie T, Narasimhan B et al (2002) Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 99:6567–6572PubMedCrossRefGoogle Scholar
  12. 12.
    Smyth GK (2004) Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3:1–10Google Scholar
  13. 13.
    Pattyn F, Speleman F, De Paepe A et al (2003) RTPrimerDB: the real-time PCR primer and probe database. Nucleic Acids Res 31:122–123PubMedCrossRefGoogle Scholar
  14. 14.
    Vandesompele J, De Preter K, Pattyn F et al (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 18:3–4Google Scholar
  15. 15.
    Flyvbjerg A, Mogensen O, Mogensen B et al (1997) Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. J Clin Endocrinol Metab 82:2308–2313PubMedCrossRefGoogle Scholar
  16. 16.
    el Atiq F, Garrouste F, Remacle-Bonnet M et al (1994) Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer. Int J Cancer 57:491–497PubMedCrossRefGoogle Scholar
  17. 17.
    Ho PJ, Baxter RC (1997) Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol 46:333–342CrossRefGoogle Scholar
  18. 18.
    Richardsen E, Ukkonen T, Bjørnsen T et al (2003) Overexpression of IGBFB2 is a marker for malignant transformation in prostate epithelium. Virchows Arch 442:329–335PubMedGoogle Scholar
  19. 19.
    Ranke MB, Maier KP, Schweizer R et al (2003) Pilot study of elevated levels of insulin-like growth factor-binding protein-2 as indicators of hepatocellular carcinoma. Horm Res 60:174–180PubMedCrossRefGoogle Scholar
  20. 20.
    Russo VC, Schütt BS, Andaloro E et al (2005) Insulin-like growth factor binding protein-2 binding to extracellular matrix plays a critical role in neuroblastoma cell proliferation, migration, and invasion. Endocrinology 146:4445–4455PubMedCrossRefGoogle Scholar
  21. 21.
    Dunlap SM, Celestino J, Wang H et al (2007) Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci U S A 104:11736–11741PubMedCrossRefGoogle Scholar
  22. 22.
    Wang H, Wang H, Shen W et al (2003) Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Res 63:4315–4321PubMedGoogle Scholar
  23. 23.
    Godard S, Getz G, Delorenzi M et al (2003) Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 63:6613–6625PubMedGoogle Scholar
  24. 24.
    Fang G, Yu H, Kirschner MW (1998) Direct binding of CDC20 protein family members activates the anaphase-promoting complex in mitosis and G1. Mol Cell 2:163–171PubMedCrossRefGoogle Scholar
  25. 25.
    Ouellet V, Guyot MC, Le Page C et al (2006) Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int J Cancer 119:599–607PubMedCrossRefGoogle Scholar
  26. 26.
    Kim JM, Sohn HY, Yoon SY et al (2005) Identification of gastric cancer-related genes using a cDNA microarray containing novel expressed sequence tags expressed in gastric cancer cells. Clin Cancer Res 11:473–482PubMedGoogle Scholar
  27. 27.
    Mondal G, Sengupta S, Panda CK et al (2007) Overexpression of CDC20 leads to impairment of the spindle assembly checkpoint and aneuploidization in oral cancer. Carcinogenesis 28:81–92PubMedCrossRefGoogle Scholar
  28. 28.
    Yuan B, Xu Y, Woo JH et al (2006) Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res 12:405–410PubMedCrossRefGoogle Scholar
  29. 29.
    Kidokoro T, Tanikawa C, Furukawa Y et al (2008) CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene 27:1562–71PubMedCrossRefGoogle Scholar
  30. 30.
    Zhang L, Huang W, Chen J et al (2007) Expression of IGFBP2 in gastric carcinoma and relationship with clinicopathologic parameters and cell proliferation. Dig Dis Sci. 52:248–253PubMedCrossRefGoogle Scholar
  31. 31.
    Elmlinger MW, Deininger MH, Schuett BS et al (2001) In vivo expression of insulin-like growth factor-binding protein-2 in human gliomas increases with the tumor grade. Endocrinology 142:1652–1658PubMedCrossRefGoogle Scholar
  32. 32.
    Yokota T, Kouno J, Adachi K et al (2006) Identification of histological markers for malignant glioma by genome-wide expression analysis: dynein, alpha-PIX and sorcin. Acta Neuropathol 111:29–38PubMedCrossRefGoogle Scholar
  33. 33.
    Boda B, Mas C, Muller D (2002) Activity-dependent regulation of genes implicated in X-linked non-specific mental retardation. Neuroscience 114:13–17PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Gianluca Marucci
    • 1
  • Luca Morandi
    • 1
  • Elisabetta Magrini
    • 1
  • Anna Farnedi
    • 1
  • Enrico Franceschi
    • 2
  • Rossella Miglio
    • 3
  • Daniela Calò
    • 3
  • Annalisa Pession
    • 1
  • Maria P. Foschini
    • 1
  • Vincenzo Eusebi
    • 1
    • 4
    Email author
  1. 1.Section of Pathology, Bellaria HospitalUniversity of BolognaBolognaItaly
  2. 2.Department of Medical OncologyBellaria HospitalBolognaItaly
  3. 3.Department of Statistics “Paolo Fortunati”University of BolognaBolognaItaly
  4. 4.Sezione di Anatomia Patologica “M. Malpighi”Ospedale BellariaBolognaItaly

Personalised recommendations